Skip to main content
VCbacked
Log inGet Started

Tenvie Therapeutics

South San Francisco, United States

Tenvie Therapeutics is a biotechnology company that transforms the treatment of neurological diseases through engineered small molecules.

$200.0M raised
Jan 2025
Series A
BiotechnologyMedicalNeuroscienceTherapeutics

Top Investors

ARCH Venture PartnersMubadala CapitalF-Prime Capital

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Tenvie Therapeutics

How much funding has Tenvie Therapeutics raised?
Tenvie Therapeutics has raised $200.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Who are Tenvie Therapeutics's investors?
Tenvie Therapeutics's investors include ARCH Venture Partners, Mubadala Capital, F-Prime Capital.
Where is Tenvie Therapeutics headquartered?
Tenvie Therapeutics is headquartered in South San Francisco, United States.
What does Tenvie Therapeutics do?
Tenvie Therapeutics is a biotechnology company that transforms the treatment of neurological diseases through engineered small molecules.
What stage is Tenvie Therapeutics at?
Tenvie Therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Tenvie Therapeutics — Funding & Investors." VCBacked, January 8, 2025, https://www.vcbacked.co/company/tenvie-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2025). Tenvie Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/tenvie-therapeutics
Wikipedia (cite web)
{{cite web |title=Tenvie Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tenvie-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong